MAPT and Alzheimer disease: Although efforts to ameliorate AD pathology have largely focused on the mechanisms underlying Aβ plaque-mediated cognitive dysfunction, the impact of the EGFR inhibitor erlotinib on tau-mediated AD pathology and cognitive function in tau-overexpressing AD mice has not been fully investigated.